Peptide-developer Xenome has signed a collaboration deal with Amylin Pharmaceuticals to develop novel peptide therapeutics for a range of metabolic and musculoskeletal diseases. Australia's Xenome separately announced that Amylin is making a $5 million equity investment in the company, part of a $10 million financing package.
- see the release on the development deal
- check out this release on the financing
Related Articles:
Psychogenics, Amylin create new development company. Report
Amylin reports weight-loss success with Symlin. Report